USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Medeon Biodesign, Inc.

USPTO PatentsView assignee record - 11 granted patents across 4 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; IDENTIFICATION).

The verdict

According to USPTO PatentsView, Medeon ranks #24,780 of 50,000 tracked US assignees by granted-patent volume, with 11 patents across 4 technology areas.

#24,780
of 50,000 US assignees by volume
Top 68%
by Innovation Score (29.7/100)
16.7
avg claims per patent
-43%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R24780 · Foreign Corporation #24,780 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MICRO 11 grants
  • MID-PACK #24,780/50,000
  • PHOTO-FINISH MBRICO
  • CPC-NARROW A61B · 4 areas
  • INNOV-THIN 29.7/100
  • CLAIMS-RICH 16.7 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DROP -43% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Mbrico, Llc (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Medeon

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Medeon's Innovation Score is 29.7/100 (top 68% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Medeon's grants concentrate

Medeon Biodesign, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). Peak complete grant year is 2019 (4 grants) versus a trough of 1 in 2017. By volume, Medeon sits between Mbrico, Llc and Melitta Europa Gmbh & Co. KG.

Medeon's three-year grant acceleration

Medeon Biodesign, Inc. shows 3 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Medeon's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Medeon holds 11 patents at rank #24,741, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Medeon

By rank, the assignees closest to #24,741 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Medeon's primary technology class.

Medeon's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 Top 68% higher than 32% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 201620172019202120232024 2
USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
Medeon Biodesign, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 2 18.2%
2017 1 9.1%
2019 4 36.4%
2021 1 9.1%
2023 1 9.1%
2024 2 18.2%

Where it ranks

Overall rank by patents

#24,780

of 50,000 tracked assignees

Innovation Score

29.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.